/PRNewswire/ The "Vulvovaginal Candidiasis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented by Drug.
/PRNewswire/ Mycovia Pharmaceuticals, Inc. ("Mycovia"), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd.
The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare sector the market is likely to propel to US$1607 Million by 2033.VVC prevalence has increased due to growing diabetes.
The global Vulvovaginal Candidiasis Treatment Market is currently valued at US$ 1035 Million in 2023 and is anticipated to expand at a CAGR of 4.5%. Owing to the technological advances in healthcare sector the market is likely to propel to US$1607 Million by 2033.VVC prevalence has increased due to growing diabetes.
According to Future Market Insights’ most recent industry report, the global Vaginal Antifungals Market size is expected to reach US$ 1.14 Billion in 2023, with a CAGR of 4.5% over the forecast period, reaching US$ 1.76 Billion in 2033.The global market for Vaginal Antifungals is expected to grow significantly over.